Tepid Q3 For Sun But Momentum In Specialty Build-Up
Sun Pharma reported a decline in profits for the third quarter amid dull US and India growth and ongoing investments to prepare for a larger play in the specialty segment, where it hopes to scale up with a mix of organic and inorganic additions to its portfolio.
You may also be interested in...
India’s biggest drug firm Sun has just launched its first branded ophthalmic product in the US, marking what the company calls “a milestone” in its quest to build scale and seek steady revenue streams in the global specialty drug business.
A new report discusses the priorities that India should focus on to leapfrog towards transformative innovation. Big pharma’s expanding global capability centres (GCCs) in India are also contributing to the innovation ecosystem while positioning the country as the global industry's “backbone”.
Glenmark hopes complex and respiratory products including a potential filing for generic Flovent pMDI can restore some lost sheen of its US business going forward, but a compliance comeback for its Monroe site may be pivotal to deliver material gains.